Anzurstobart, a fully human monoclonal anti-SIRPalpha antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPalpha interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.
Purity:
95.00%
CAS Number:
[2543693-10-1]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted
